Condition: Cytomegalovirus Infections · Infection in Solid Organ Transplant Recipients · Neutropenia · Sponsor: Tufts Medical Center
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
This description comes directly from the study's public registry record.
Jennifer K Chow, MD, MS · 617-636-5244 · Jennifer.Chow@TuftsMedicine.org
Whitney K Perry, MD, MS · 339-368-0047 · Whitney.Perry@tuftsMedicine.org
Always discuss trial participation with your own doctor first.
| Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05626530